Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis.

Gynecologic oncology - 1 Apr 2023

Hendrikse C S E, Theelen P M M, van der Ploeg P, Westgeest H M, Boere I A, Thijs A M J, Ottevanger P B, van de Stolpe A, Lambrechts S, Bekkers R L M, Piek J M J

Abstract excerpt

BACKGROUND: The RAS/RAF/MEK/ERK (MAPK) pathway plays a role in ovarian carcinogenesis. Low-grade serous ovarian carcinoma (LGSOC) frequently harbors activating MAPK mutations. MAPK inhibitors have been used in small subsets of ovarian carcinoma (OC) patients to control tumor growth. Therefore, we performed a meta-analysis to evaluate the effectiveness of MAPK inhibitors in OC patients. We aimed to determine the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Ovarian Epithelial
Share to MAP Kinase Signaling System

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mitogen-Activated Protein Kinase Kinases

Share to Mutation

Share to Ovarian Neoplasms

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Signal Transduction

Source

Identifiers

PMID: 36841040
DOI: 10.1016/j.ygyno.2023.01.038

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis.PMID 36841040Read ↗

Low grade serous ovarian cancer - A rare disease with increasing therapeutic options.Semantic proximity Read ↗

The RAS-MEK-ERK pathway in low-grade serous ovarian cancer.Semantic proximity Read ↗

Co-targeting the PI3K-Akt pathway improves response to MEK inhibition in low-grade serous ovarian cancer cell linesSemantic proximity Read ↗

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.Semantic proximity Read ↗

Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic targetSemantic proximity Read ↗

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma.Semantic proximity Read ↗

Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.Semantic proximity Read ↗

Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on KRAS/NF1 Mutational Status.Semantic proximity Read ↗

The MEK1/2 pathway as a therapeutic target in high-grade serous ovarian carcinomaSemantic proximity Read ↗

Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives.Semantic proximity Read ↗

Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological Cancer Harboring RAS Mutation: A Case Series.Semantic proximity Read ↗

Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.